Erasca Faces Class Action Lawsuit Over Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: Globenewswire
Erasca Inc. saw its stock price rise by 8.36% and reach a 20-day high despite the broader market decline, with the Nasdaq-100 down 1.06% and the S&P 500 down 0.16%.
The recent class action lawsuits filed against Erasca allege that the company made false and misleading statements regarding its drug candidate ERAS-0015's preclinical data, which has raised significant concerns among investors. These lawsuits, initiated by multiple law firms, highlight the potential for substantial investor losses due to alleged patent and trade secret violations. The legal actions have prompted affected investors to seek representation, with deadlines approaching for lead plaintiff applications.
The implications of these lawsuits could be profound for Erasca, as they not only threaten the company's reputation but also its financial stability. Investors are advised to stay informed about the developments in these legal proceedings, as they may impact stock performance in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
Current: 18.850
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiff by August 10, 2026, to represent other shareholders in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting the Rosen Law Firm website or calling the toll-free number for more information, with no upfront fees required, ensuring the protection of investor rights.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations from Revolution Medicines of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further investor losses.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which may undermine investor confidence in its product offerings.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, exacerbating concerns over the product's safety and potentially impacting future clinical trials and market rollout.
See More
Erasca Faces Class Action Lawsuit Risk
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations of patent infringement against Revolution Medicines, impacting investors who purchased stock between January 14, 2025, and April 26, 2026, highlighting significant legal risks in the company's drug development.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 after receiving a legal letter, indicating strong market reactions to the company's legal troubles.
- Clinical Data Disclosure: The same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death one month after starting treatment, causing the stock to plummet further by $9.25, or 48.3%, to $9.90 on April 28, severely harming investor interests.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose significant adverse facts regarding ERAS-0015, misleading investors about the company's prospects and reflecting a critical lack of transparency in corporate communications.
See More
Investigation Launched into Erasca Securities Litigation
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Erasca, Inc. due to false statements made between January 14, 2025, and April 26, 2026, which may have led to significant investor losses.
- Stock Price Plunge: On April 27, 2026, after disclosing clinical data for its ERAS-0015 drug, Erasca's stock price plummeted from $21.49 to $9.90, a drop of over 45%, indicating strong market concerns about the company's future.
- Investor Rights: Affected investors are encouraged to contact Faruqi & Faruqi for legal support, particularly those who purchased Erasca shares during the class period, with a deadline to seek lead plaintiff status by August 10, 2026.
- Potential Liability: The lawsuit alleges that Erasca and its executives failed to disclose risks of patent infringement related to Revolution Medicines, Inc., leading to investor misunderstandings about the company's prospects and potential for substantial liability.
See More
Erasca Shareholder Class Action Notice
- Class Action Deadline: Shareholders of Erasca, Inc. (NASDAQ: ERAS) must apply to be lead plaintiffs in the class action lawsuit by August 10, 2026, or risk losing their opportunity to represent other shareholders in the litigation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of making false and misleading statements about its oncology drug candidate ERAS-0015 from January 14, 2025, to April 26, 2026, resulting in investor losses when the truth emerged.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record in class actions to ensure effective representation, cautioning against firms that merely act as intermediaries.
- Historical Achievements: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, underscoring its strong reputation in securities litigation.
See More
Erasca Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, alleging that the company made materially false and misleading statements that inflated stock prices during this period.
- Claims for Damages: The lawsuit claims that due to the defendants' misrepresentations, Erasca's common stock traded at artificially inflated prices, resulting in significant losses for investors when the truth was revealed, prompting demands for compensation for affected shareholders.
- Participation Guidance: Investors are encouraged to act promptly and submit a form to participate in the lawsuit; those wishing to serve as lead plaintiff must file by August 10, 2026, with all representation on a contingency fee basis, meaning shareholders incur no fees.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its success in litigating class actions, highlighting its strong reputation in the securities litigation field.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiff by August 10, 2026, to represent other shareholders in the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting the Rosen Law Firm website or calling the toll-free number for more information, with no upfront fees required, ensuring the protection of investor rights.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations from Revolution Medicines of patent infringement, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further investor losses.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which may undermine investor confidence in its product offerings.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, the market reacted sharply, exacerbating concerns over the product's safety and potentially impacting future clinical trials and market rollout.
See More
Erasca Faces Class Action Lawsuit Risk
- Lawsuit Background: Erasca, Inc. is facing a class action lawsuit due to allegations of patent infringement against Revolution Medicines, impacting investors who purchased stock between January 14, 2025, and April 26, 2026, highlighting significant legal risks in the company's drug development.
- Stock Price Plunge: On April 27, 2026, Erasca's stock price fell by $2.34, or 10.9%, closing at $19.15 after receiving a legal letter, indicating strong market reactions to the company's legal troubles.
- Clinical Data Disclosure: The same day, Erasca reported preliminary clinical data for ERAS-0015, revealing a patient death one month after starting treatment, causing the stock to plummet further by $9.25, or 48.3%, to $9.90 on April 28, severely harming investor interests.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, Erasca failed to disclose significant adverse facts regarding ERAS-0015, misleading investors about the company's prospects and reflecting a critical lack of transparency in corporate communications.
See More
Investigation Launched into Erasca Securities Litigation
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Erasca, Inc. due to false statements made between January 14, 2025, and April 26, 2026, which may have led to significant investor losses.
- Stock Price Plunge: On April 27, 2026, after disclosing clinical data for its ERAS-0015 drug, Erasca's stock price plummeted from $21.49 to $9.90, a drop of over 45%, indicating strong market concerns about the company's future.
- Investor Rights: Affected investors are encouraged to contact Faruqi & Faruqi for legal support, particularly those who purchased Erasca shares during the class period, with a deadline to seek lead plaintiff status by August 10, 2026.
- Potential Liability: The lawsuit alleges that Erasca and its executives failed to disclose risks of patent infringement related to Revolution Medicines, Inc., leading to investor misunderstandings about the company's prospects and potential for substantial liability.
See More
Erasca Shareholder Class Action Notice
- Class Action Deadline: Shareholders of Erasca, Inc. (NASDAQ: ERAS) must apply to be lead plaintiffs in the class action lawsuit by August 10, 2026, or risk losing their opportunity to represent other shareholders in the litigation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of making false and misleading statements about its oncology drug candidate ERAS-0015 from January 14, 2025, to April 26, 2026, resulting in investor losses when the truth emerged.
- Choosing Legal Counsel: The Rosen Law Firm advises investors to select qualified legal counsel with a proven track record in class actions to ensure effective representation, cautioning against firms that merely act as intermediaries.
- Historical Achievements: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, underscoring its strong reputation in securities litigation.
See More
